Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib in untreated limited-stage small cell lung cancer
CTR20210114Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, olaparib in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Apr 2021; status: active.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20210114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210114.